Adverum Biotechnologies (ADVM) BidaskScore is increased to Held

Adverum Biotechnologies

The BidaskScore of Adverum Biotechnologies ADVMADVM shows that the shares of the company are now ADVMStrongly Bought Held by investors.

The BidaskScore of the BiotechnologyBiotechnology shows that the sector is BiotechnologyStrongly Bought Sold since January 4.

Here are the BidAskScore of other related companies in the Biotechnology sector:

Adverum Biotechnologiesˌ Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet age-related macular degenerationˌ alpha-1 antitrypsin deficiencyˌ hereditary angioedemaˌ friedreichʿs ataxiaˌ severe allergyˌ color vision deficiencyˌ and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranzˌ Thomas W. Chalbergˌ Jr. and Steven Daniel Schwartz on July 17ˌ 2006 and is headquartered in Menlo Parkˌ CA.

Adverum Biotechnologies

Launched in 2016, the BidAskClubBidaskClub allows users to follow the evolution of the US equity market. BidaskClub provides a platform to create portfolios and be informed when a company´s or sector’s BidaskScore changes. BidaskClub is provided by LuxFinAdviceLuxFinAdvice.